by applying the latest science, technology and research, guardion health sciences (ghs) has positioned itself to address the escalating demand for solutions that promise to improve life-diminishing health problems facing the aging baby boomer generation. guardion health sciences is dedicated to applying a scientific discipline and pharmaceutical approach to the development of safe, standardized and effective condition specific solutions. using the individual and collective knowledge of the members of our science advisory board, we will advise healthcare professionals and the public on the importance of medical foods and nutrition to achieve overall good health. the company’s first medical food, lumega-z, is scientifically formulated to restore and maintain the macular protective pigment. a depleted macular pigment is a known contributor to amd. though lumega-z was created with the amd epidemic in mind, its ingredients are also thought to be beneficial for other types of eye disease (i.
Company profile
Ticker
GHSI
Exchange
Website
CEO
David W. Evans
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Guardion Health Sciences, LLC
SEC CIK
Corporate docs
Subsidiaries
VectorVision Ocular Health, Inc. • Transcranial Doppler Solutions, Inc. • NutriGuard Formulations, Inc. • Viactiv Nutrititionals, Inc. ...
IRS number
474428421
GHSI stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
9 Apr 24
DEFM14A
Proxy related to merger
8 Apr 24
S-3
Shelf registration
2 Apr 24
8-K
Guardion Health Sciences Announces Financial Results
1 Apr 24
PREM14A
Preliminary proxy related to merger
20 Mar 24
PRE 14A
Preliminary proxy
15 Mar 24
425
Business combination disclosure
31 Jan 24
8-K
Entry into a Material Definitive Agreement
31 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
21 Nov 23
8-K
Guardion Health Sciences Announces Financial Results
13 Nov 23
Transcripts
Latest ownership filings
3
Initial statement of insider ownership
3 Apr 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
5 Feb 24
3
Katharine Joan Cox
7 Aug 23
4
ROBERT N WEINGARTEN
5 Jul 23
4
Donald A Gagliano
5 Jul 23
4
Michaela Griggs
5 Jul 23
4
Mark Goldstone
5 Jul 23
4
Janet Hall
31 May 23
3
Janet Hall
31 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.66 mm | 7.66 mm | 7.66 mm | 7.66 mm | 7.66 mm | 7.66 mm |
Cash burn (monthly) | 236.23 k | 440.72 k | 257.64 k | 1.22 mm | 255.53 k | 368.02 k |
Cash used (since last report) | 1.60 mm | 2.99 mm | 1.75 mm | 8.26 mm | 1.74 mm | 2.50 mm |
Cash remaining | 6.05 mm | 4.66 mm | 5.91 mm | -606.98 k | 5.92 mm | 5.16 mm |
Runway (months of cash) | 25.6 | 10.6 | 22.9 | -0.5 | 23.2 | 14.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 87.40 mm |
Total shares | 5.07 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 5.00 mm | $0.00 |
Renaissance Technologies | 37.62 k | $293.00 k |
Radoff Bradley Louis | 25.10 k | $174.00 k |
BLK Blackrock | 10.03 k | $78.03 mm |
BCS Barclays | 900.00 | $7.00 k |
MS Morgan Stanley | 659.00 | $5.13 mm |
C Citigroup | 373.00 | $2.84 mm |
UBS UBS Group AG - Registered Shares | 43.00 | $335.00 k |
Roffman Miller Associates | 40.00 | $311.00 k |
Signaturefd | 20.00 | $156.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 May 23 | Janet Hall | Stock option Common Stock | Grant | Acquire A | No | No | 6.01 | 10,000 | 60.10 k | 10,000 |
News
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
9 Apr 24
11 Consumer Staples Stocks Moving In Thursday's Intraday Session
8 Feb 24
Maxim Group Downgrades Guardion Health Sciences to Hold
2 Feb 24
Why Guardion Health Sciences Stock Is Up Today
31 Jan 24
Press releases
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
29 Mar 24
Thinking about buying stock in Guardion Health Sciences, Minim, Revelation Biosciences, Nyxoah, or Pixelworks?
31 Jan 24
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor's Best Inc.
30 Jan 24